Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.52 |
| ▸ | F10 | P00742 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3838911 | 0.99 | HTR4 (0.63) | SMN1; SMN2HTR4LMNAPOLBKMT2A | |
| SCHEMBL3770520 | 0.90 | LMNA (0.74) | SMN1; SMN2LMNAPOLBKMT2AALDH1A1 | |
| SCHEMBL1185868 | 0.86 | HTR4 (0.67) | SMN1; SMN2HTR4LMNAPOLBALDH1A1 | |
| SCHEMBL1186358 | 0.85 | HTR4 (0.69) | SMN1; SMN2HTR4LMNAPOLBALDH1A1 | |
| SCHEMBL15536928 | 0.83 | KMT2A (0.65) | SMN1; SMN2HTR4LMNAPOLBKMT2A | |
| SCHEMBL3542972 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2HTR4POLBKMT2ASLC5A7 | |
| SCHEMBL9995247 | 0.80 | ALDH1A1 (0.77) | SMN1; SMN2HTR4LMNAPOLBALDH1A1 | |
| SCHEMBL13575582 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2HTR4POLBKMT2ASLC5A7 | |
| SCHEMBL14924433 | 0.80 | SMN1; SMN2 (0.70) | SMN1; SMN2POLBKMT2ASLC5A7ALDH1A1 | |
| SCHEMBL1184262 | 0.80 | LMNA (0.59) | SMN1; SMN2HTR4LMNAPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7850948-B2 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | BAYER SCHERING PHARMA AG (DE) | 2010-12-14 | — | — | US | disclosed |
| US-20090012090-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | FRIEBE MATTHIAS | 2009-01-08 | — | — | US | disclosed |
| US-7427390-B2 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | SCHERING AG (DE) | 2008-09-23 | — | — | US | disclosed |
| US-20050207972-A1 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012090-A1 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy | BRDT, AADAC, IDH2 | SMN1; SMN2 4756/4885HTR4 1709/4885LMNA 3376/4885 |
| US-20050207972-A1 | Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy | BRDT, AADAC, IDH2 | SMN1; SMN2 4756/4885HTR4 1709/4885LMNA 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.